Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study

Jinghao Nicholas Ngiam, Enoch Xueheng Loy, Matthew Chung Yi Koh, Calvin J. Chiew, Russell Jingxian Li, Su Chi Lim, E Shyong Tai, Yong Mong Bee, Wai Leng Chow, David Chien Boon Lye, Yew Woon Chia, Mark Yan Yee Chan, Derek J. Hausenloy, Kelvin Bryan Tan, Liang En Wee · 2026

Read Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study by Jinghao Nicholas Ngiam, Enoch Xueheng Loy, Matthew Chung Yi Koh, Calvin J. Chiew, Russell Jingxian Li, Su Chi Lim, E Shyong Tai, Yong Mong Bee, Wai Leng Chow, David Chien Boon Lye, Yew Woon Chia, Mark Yan Yee Chan, Derek J. Hausenloy, Kelvin Bryan Tan, Liang En Wee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13280275.txt.

Description

Jinghao Nicholas Ngiam and colleagues published a 2026 nationwide cohort study of whether two diabetes drugs taken before COVID-19 infection lowered the risk of long COVID. People with type 2 diabetes face high risk of lingering post-infection problems. Using national claims data from 2021 to 2023, the team followed 71,698 patients. The analysis was weighted to balance age, vaccination, other illnesses, and healthcare use between users and non-users of SGLT2 inhibitors and metformin.

Prior SGLT2 inhibitor use was tied to lower risk of neurological after-effects, with an adjusted hazard ratio of 0.60, and to fewer lingering symptoms. Metformin use was also associated with lower post-acute risk and fewer symptoms. Both drugs together reduced neurological problems beyond metformin alone. The authors note the design is observational, so the drugs may be markers of other advantages rather than the cause. The consistency supports prospective testing of these medicines for post-COVID protection.

Catalog record

CREATORJinghao Nicholas Ngiam, Enoch Xueheng Loy, Matthew Chung Yi Koh, Calvin J. Chiew, Russell Jingxian Li, Su Chi Lim, E Shyong Tai, Yong Mong Bee, Wai Leng Chow, David Chien Boon Lye, Yew Woon Chia, Mark Yan Yee Chan, Derek J. Hausenloy, Kelvin Bryan Tan, Liang En Wee
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13280275

Browse the full library · About the Tower of Babel